PFPeptide File
Live Updates
NEWRetatrutide Phase III results — 28.7% body weight reduction confirmed at 12mg/68 weeks·UPDATECJC-1295 half-life study published in Journal of Endocrinology·TRIALBPC-157 human trial enrolment opens Q3 2026·FDARetatrutide NDA submission expected late 2026·RESEARCHNew GLP-1/GIP dual agonist data vs tirzepatide head-to-head·NEWRetatrutide Phase III results — 28.7% body weight reduction confirmed at 12mg/68 weeks·UPDATECJC-1295 half-life study published in Journal of Endocrinology·TRIALBPC-157 human trial enrolment opens Q3 2026·FDARetatrutide NDA submission expected late 2026·RESEARCHNew GLP-1/GIP dual agonist data vs tirzepatide head-to-head·
Recovery & Healing Peptide

The TB-500 File

Research compound (not FDA approved) · N/A — synthetic thymosin beta-4 fragment

Moderate Evidence

Synthetic fragment of thymosin beta-4. Used alongside BPC-157 for injury recovery. Primarily studied in animal models with promising wound healing data.

Mechanism

Promotes cell migration, blood vessel growth, and reduces inflammation for tissue repair

Key Data

primary Use

Wound healing, muscle recovery, inflammation reduction

evidence Base

Animal studies, limited human data

related Compound

Thymosin beta-4

common Side Effects

  • · Headache
  • · Injection site irritation

Full Article Coming Soon

The full The TB-500 File will cover mechanism of action, clinical trial evidence, dosage data, side effects, comparisons, and FAQs — all evidence-rated and referenced. Check back soon.

This content is for informational purposes only. Not medical advice. Always consult a qualified healthcare provider before making any health decisions.

The weekly peptide brief.

One email per week. Evidence-rated research summaries on peptides and metabolic science. No hype. No selling. Unsubscribe anytime.

No spam. No selling. Unsubscribe with one click.